Overview

  • Product nameAnti-Nmnat1 antibody [1F7]See all Nmnat1 primary antibodies ...
  • Description
    Mouse monoclonal [1F7] to Nmnat1
  • Tested applicationsWB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein, corresponding to amino acids 1-279 of Human Nmnat1, produced in HEK293T cells (NP_073624).

  • Positive control
    • Nmnat1 transfected HEK293T cell lysate and COS7 cells transiently transfected with Nmnat1

Properties

Applications

Our Abpromise guarantee covers the use of ab118270 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Predicted molecular weight: 31 kDa.
ICC/IF 1/100.

Target

  • FunctionCatalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, prefers NAD(+) and NAAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NAADP(+). Protects against axonal degeneration following mechanical or toxic insults.
  • Tissue specificityWidely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
  • PathwayCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
  • Involvement in diseaseDefects in NMNAT1 are the cause of Leber congenital amaurosis 9 (LCA9) [MIM:608553]. A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus.
  • Sequence similaritiesBelongs to the eukaryotic NMN adenylyltransferase family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC 2.7.7.1 antibody
    • LCA9 antibody
    • Leber's congenital amaurosis 9 antibody
    • NaMN adenylyltransferase 1 antibody
    • Nicotinamide mononucleotide adenylyltransferase 1 antibody
    • nicotinamide nucleotide adenylyltransferase 1 antibody
    • nicotinate nucleotide adenylyltransferase 1 antibody
    • Nicotinate-nucleotide adenylyltransferase 1 antibody
    • NMN adenylyltransferase 1 antibody
    • NMNA1_HUMAN antibody
    • Nmnat 1 antibody
    • Nmnat1 antibody
    • OTTHUMP00000001731 antibody
    • OTTHUMP00000001732 antibody
    • OTTHUMP00000035892 antibody
    • PNAT 1 antibody
    • PNAT1 antibody
    • pyridine nucleotide adenylyltransferase 1 antibody
    see all

Anti-Nmnat1 antibody [1F7] images

  • All lanes : Anti-Nmnat1 antibody [1F7] (ab118270) at 1/2000 dilution

    Lane 1 : Non transfected cell lysate
    Lane 2 : Nmnat1 transfected HEK293T cell lysate

    Lysates/proteins at 5 µg per lane.


    Predicted band size : 31 kDa
  • ab118270, at 1/100, staining Nmnat1 in COS7 cells transiently transfected with Nmnat1, by immunofluorescence.

References for Anti-Nmnat1 antibody [1F7] (ab118270)

ab118270 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab118270.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"